-transparent.png){kind=logo}
In order to develop a model for the putative binding sites between the D2 dopamine receptor and many of its agonists, we obtained the dissociation constants of many dopaminergic agonists at the high affinity state, D2high, as well as at the low affinity state, D2low, of the receptor. [3H]Spiperone was used to label the D2 dopamine receptors in porcine anterior pituitary tissue. Agonists without any hydroxyl groups, such as 2-aminotetralin, effectively inhibited the binding of [3H]spiperone; the addition of a hydroxyl group corresponding to the "meta" position in dopamine, however, enhanced the potency (in four series of agonists) by an order of magnitude. The R-(-)-enantiomers of the aporphines and 5,6,-dihydroxy-2-dipropylaminotetralin were more potent than the S-(+)-enantiomers. Although the 4-methoxy-2-dipropylaminoindans were potent, the R-(-)-11-methoxyaporphines were not. A tetrahedral model is proposed; this has two sites for agonist attachment, the extremities of the sites being separated by 8 A, and their functional groups directed between 15 degrees and 30 degrees off the orthogonal from the receptor surface. Several steric obstacles are required to account for the inactivity of several congeners.
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
June 1988,
The Journal of pharmacy and pharmacology,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
December 1996,
Brain research,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
January 1992,
Progress in medicinal chemistry,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
June 1998,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
June 1993,
European journal of pharmacology,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
February 1999,
Neuroreport,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
May 2020,
CNS drugs,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
July 2003,
Neurochemical research,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
February 1994,
Drug design and discovery,
P Seeman, and
M Watanabe, and
D Grigoriadis, and
J L Tedesco, and
S R George, and
U Svensson, and
J L Nilsson, and
J L Neumeyer
January 1989,
Progress in clinical and biological research,
